CAR T-cell Therapy Causes Heavy Financial Losses for Hospitals
Chimeric antigen receptor (CAR) T-cell therapy has been hailed as a game changer for advanced blood cancers because the treatment has elicited responses and complete remissions in patients who have come to the end of approved treatment options. At the same time, however, these therapies have redefined the meaning of expensive.
